P-003: A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)
Titel:
P-003: A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)
Auteur:
Kumar, Shaji Kapoor, Prashant Alencar, Alvaro Murthy, Guru Subramanian Guru Hoffmann, Marc Pagel, John Patel, Vishalkumar Pauff, James Zinzani, Pier Luigi Gouill, Steven Le Mato, Anthony R. Jurczak, Wojciech Roeker, Lindsey E.